Home/Pipeline/VV119

VV119

Schizophrenia

Phase 1Active

Key Facts

Indication

Schizophrenia

Phase

Phase 1

Status

Active

Company

About Vigonvita

A Chinese biopharma company with a fully integrated platform developing and commercializing drugs for viral infections, neuropsychiatry, and reproductive health.

View full company profile

Therapeutic Areas

Infectious Disease Neurology Psychiatry Urology/Reproductive Health

Other Schizophrenia Drugs

Drug	Company	Phase	Status
DB103 (Pomaglumetad)	Denovo Biopharma	Phase 2b/3	Active
ZZ6398	Zhongze Therapeutics	Phase 1/2	Active
RBP-7000 (PERSERIS®)	Indivior	Marketed	Commercial
Undisclosed Programs	Johnson and Johnson Innovative Medicine	Pipeline	Active
Schizophrenia Candidate	Teva	Phase 3	Active
Schizophrenia Model Service	NeuroProof	Pre-clinical	Active
LYN-005 (Nortiva)	Lyndra	Phase 3	Active
TerXT	Terran Biosciences	Late-stage (Pre-Phase 3)	Active
Undisclosed Program	Curemark	Preclinical	Active
Schizophrenia Intermediate	OFD Biopharma	Proof of concept	Active
Schizophrenia	Keltic Pharma Therapeutics	Pre-clinical	Active
AVAT-031	Avata Biosciences	Discovery	Active